Where Is the Data? Delayed and Chronic irAE Surveillance and Management After Cessation of ICIs: Expert Insights From SITC on Survivorship Care and the Need for Long-Term Data

    March 2026 in “ Journal for ImmunoTherapy of Cancer ”
    Tessa Flores, Emily S. Tonorezos, Shailender Bhatia … Marc S Ernstoff
    Studysummary This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jitc.bmj.com →
    Discuss this study in the Community →